A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Active, not recruiting · Phase 3 · NCT06075667
Conditions: Obesity, Overweight
At a glance
- Research payments reported, 2025
- $1.2M
- U.S. investigators named
- 10
- Sites paid
- 16
- Planned or actual enrollment
- 160
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Tirzepatide (drug), Placebo (drug)
- Dates
- Started 2023-10-16; completion 2029-07
- Results posted
- Not yet
The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity. The study will last approximately 90 weeks and may include up to 25 visits. Participants who have completed the primary 72-week GPHP study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the opportunity to receive an additional 156 weeks of treatment with tirzepatide as well as continuing the lifestyle intervention.
From ClinicalTrials.gov, last updated 2026-06-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $1.2M in research payments for this study in 2025 (25 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Kimball A. Johnson, MD Internal Medicine · Atlanta, GA
- David Butuk, MD Family Medicine · Meridian, ID
- Alan G. Wynne, MD Endocrinology & Diabetes · Topeka, KS
- Stewart T. Gordon, MD Pediatrics · Baton Rouge, LA
- Barry J. Reiner, M.D. Pediatric Endocrinology · Baltimore, MD
- Claudia K. Fox, MD Pediatrics · Minneapolis, MN
- Jennifer E. Sprague, MD Pediatric Endocrinology · Saint Louis, MO
- Rogelio V. Amisola, MD Pediatrics · Beavercreek, OH
- Sridhar Guduri, M.D Allergy & Immunology · Dublin, OH
- Gitanjali Srivastava, M.D. Obesity Medicine · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Cr Services Acquisition US LLC $222,599
- Barry J Reiner MD LLC $206,053
- Cenexel Iresearch LLC $150,571
- Vanderbilt University Medical Center, TN $143,305
- Primed Clinical Research LLC $128,420
- Regents of the University of Minnesota $107,500
- Solaris Clinical Research LLC $82,046
- Cotton Oneil Msd of Stormont Vail Healthcare $72,126
- Board of Supervisors of La State $64,189
- Washington University $49,443
- Columbus Clinical Research Inc $669
- Healtheast Medical Research Institute $573
- Pennington Biomedical Research Foundation $309
- $261
- Vanderbilt University Medical Center $230
- Seattle Institute for Biomed and Clinical Rsrch $195
- Stormont-Vail Healthcare Inc $109
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.